Advanced

Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.

Niméus, Emma LU ; Koliadi, A; Ahlin, C; Holmqvist, M; Holmberg, Lars; Amini, R-M; Jirström, Karin LU ; Wärnberg, F; Blomqvist, C and Fernö, Mårten LU , et al. (2010) In International Journal of Cancer 127. p.961-967
Abstract
A large proportion of women with lymph node negative breast cancer treated with chemotherapy do not benefit from such treatment. Proliferation markers have been shown to recognize patients at high risk for recurrence. Ki67 has recently been included in the St Gallen guidelines. We investigated the prognostic importance of cyclin B1 in node negative breast cancer and included a study of reproducibility. In a population-based case-control study 190 women who died from breast cancer were defined as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size < 50 mm, no lymph node metastases, and no adjuvant chemotherapy. Tumor tissue was immunostained for cyclin B1. Two... (More)
A large proportion of women with lymph node negative breast cancer treated with chemotherapy do not benefit from such treatment. Proliferation markers have been shown to recognize patients at high risk for recurrence. Ki67 has recently been included in the St Gallen guidelines. We investigated the prognostic importance of cyclin B1 in node negative breast cancer and included a study of reproducibility. In a population-based case-control study 190 women who died from breast cancer were defined as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size < 50 mm, no lymph node metastases, and no adjuvant chemotherapy. Tumor tissue was immunostained for cyclin B1. Two investigators evaluated the staining independently by counting approximately 100, 200, 500, and 1000 cells. Cyclin B1 was statistically significantly associated to breast cancer death, in both uni- and multivariate analyses (adjusted for tumor size, age, and endocrine therapy), with odds ratios 2-3 for both investigators. The agreement between the two investigators was good to very good, regardless of the number of counted cells (kappa values between 0.74 and 0.82).Cyclin B1 is a prognostic factor for breast cancer death in a population-based node negative patient cohort which can identify high-risk patients with a good to very good reproducibility. (c) 2009 UICC. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Cancer
volume
127
pages
961 - 967
publisher
John Wiley & Sons
external identifiers
  • wos:000279971500023
  • pmid:19957331
  • scopus:77954737040
ISSN
0020-7136
DOI
10.1002/ijc.25091
language
English
LU publication?
yes
id
efb6f54a-7e00-4904-ba7c-68e89624a1d5 (old id 1524051)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19957331?dopt=Abstract
date added to LUP
2010-01-14 09:00:45
date last changed
2018-05-29 11:30:42
@article{efb6f54a-7e00-4904-ba7c-68e89624a1d5,
  abstract     = {A large proportion of women with lymph node negative breast cancer treated with chemotherapy do not benefit from such treatment. Proliferation markers have been shown to recognize patients at high risk for recurrence. Ki67 has recently been included in the St Gallen guidelines. We investigated the prognostic importance of cyclin B1 in node negative breast cancer and included a study of reproducibility. In a population-based case-control study 190 women who died from breast cancer were defined as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size &lt; 50 mm, no lymph node metastases, and no adjuvant chemotherapy. Tumor tissue was immunostained for cyclin B1. Two investigators evaluated the staining independently by counting approximately 100, 200, 500, and 1000 cells. Cyclin B1 was statistically significantly associated to breast cancer death, in both uni- and multivariate analyses (adjusted for tumor size, age, and endocrine therapy), with odds ratios 2-3 for both investigators. The agreement between the two investigators was good to very good, regardless of the number of counted cells (kappa values between 0.74 and 0.82).Cyclin B1 is a prognostic factor for breast cancer death in a population-based node negative patient cohort which can identify high-risk patients with a good to very good reproducibility. (c) 2009 UICC.},
  author       = {Niméus, Emma and Koliadi, A and Ahlin, C and Holmqvist, M and Holmberg, Lars and Amini, R-M and Jirström, Karin and Wärnberg, F and Blomqvist, C and Fernö, Mårten and Fjällskog, M-L},
  issn         = {0020-7136},
  language     = {eng},
  pages        = {961--967},
  publisher    = {John Wiley & Sons},
  series       = {International Journal of Cancer},
  title        = {Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.},
  url          = {http://dx.doi.org/10.1002/ijc.25091},
  volume       = {127},
  year         = {2010},
}